BSIM Therapeutics is awarded a European Patent

BSIM Therapeutics has been awarded a European Patent (Patent no. 3.307.723.B1) for one of its transthyretin (TTR) stabilization technologies showing potential for the treatment of TTR-mediated amyloidosis (ATTR). Said technology has also been granted patent protection in the United States of America (Patent no. 10,377,729) in August 2019. Altogether, the technologies under development by BSIM are intended to address a wide spectrum of ATTR manifestations that represent challenging and unmet medical needs. As we strive to achieve this goal, further TTR stabilization technologies are underway. Stay tuned!